Study on Induction Therapy for Patients with FLT3 Mutated Acute Myeloid Leukemia

Sponsor: Guenther Koehne

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT04982354

Provider View

This clinical trial is exploring a new treatment approach for patients with high-risk FLT3 mutated acute myeloid leukemia (AML). The study combines a chemotherapy drug, CPX-351, with a targeted therapy, midostaurin, to see if it can improve outcomes before and after a stem cell transplant.

Patient Parameters

Program Overview

The purpose of this study is to test a new treatment combination for patients with high-risk FLT3 mutated acute myeloid leukemia (AML). The treatment involves using a chemotherapy drug called CPX-351 along with a targeted therapy drug called midostaurin. This combination is given as part of the initial treatment (induction) and continued to help maintain remission (consolidation) before patients receive a stem cell transplant from a compatible donor.

Eligibility Criteria

Inclusion Criteria

  • Patients must have a performance status score of at least 70%, meaning they are able to carry out normal activities with some effort.
  • Patients must have adequate organ function as determined by specific medical tests.

Exclusion Criteria

  • Female patients who are pregnant or breastfeeding cannot participate.
  • Patients with active viral, bacterial, or fungal infections are not eligible.
  • Patients who test positive for HIV or HTLV are excluded.
  • Patients with leukemia that has spread to the central nervous system (CNS) are not eligible.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.